Rhumbline Advisers Raises Stock Position in BrainsWay Ltd. (NASDAQ:BWAY)

Rhumbline Advisers raised its stake in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,966 shares of the company’s stock after purchasing an additional 2,144 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of BrainsWay worth $207,000 at the end of the most recent reporting period.

Separately, JPMorgan Chase & Co. increased its position in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after purchasing an additional 11,221 shares during the period. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Stock Down 2.3 %

Shares of NASDAQ BWAY opened at $9.19 on Tuesday. The firm’s 50-day moving average price is $10.21 and its 200-day moving average price is $9.57. The company has a market cap of $173.02 million, a PE ratio of 91.91 and a beta of 1.29. BrainsWay Ltd. has a 52-week low of $4.61 and a 52-week high of $11.79.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of BrainsWay in a research report on Monday, December 23rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.